SCHEMBL3374117

SCHEMBL3374117

CC(C)(Oc1cccc(Cl)c1)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 9/20 0.64
CYP2C19 P33261 2/20 0.64
MEN1 O00255 1/20 0.64
CYP1A2 P05177 1/20 0.64
CYP3A4 P08684 1/20 0.64
CYP2D6 P10635 1/20 0.64
MAPT P10636 1/20 0.64
KMT2A Q03164 1/20 0.64
PPARG P37231 7/20 0.55
FABP2 P12104 1/20 0.55
SLC22A12 Q96S37 1/20 0.55
MAP4K4 O95819 1/20 0.52
CNR1 P21554 2/20 0.49
HSD11B1 P28845 2/20 0.49
HSD11B2 P80365 2/20 0.49
CNR2 P34972 1/20 0.49
PTPN7 P35236 1/20 0.49
DUSP3 P51452 1/20 0.49
PTPN12 Q05209 1/20 0.49
PTPN22 Q9Y2R2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11377777 0.88 PPARG (0.58) PPARACYP2C19MEN1CYP1A2CYP3A4
SCHEMBL17859584 0.86 HSD11B1 (0.46) PPARACYP2C19MEN1CYP1A2CYP3A4
SCHEMBL9588829 0.86 HSD11B1 (0.49) PPARACYP2C19MEN1CYP1A2CYP3A4
SCHEMBL3845579 0.82 PPARG (0.56) PPARACYP2C19MEN1CYP1A2CYP3A4
SCHEMBL3526757 0.82 PPARA (0.67) PPARACYP2C19MEN1CYP1A2CYP3A4
SCHEMBL7991799 0.81 OGG1 (0.55) PPARACYP2C19MEN1CYP1A2CYP3A4
SCHEMBL9911068 0.81 PPARG (0.55) PPARACYP2C19MEN1CYP1A2CYP3A4
SCHEMBL7988206 0.81 PPARA (0.55) PPARACYP2C19MEN1CYP1A2CYP3A4
SCHEMBL21378829 0.81 PPARG (0.74) PPARACYP2C19MEN1CYP1A2CYP3A4
SCHEMBL11388366 0.81 PPARG (0.74) PPARACYP2C19MEN1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1217884-B1 METHOD FOR MATURATION OF CONIFER SOMATIC EMBRYOS WOODY PLANT BIOTECH APS (DK) 2007-02-21 EP claimed
US-6897065-B1 Method for maturation of conifer somatic embryos WOODY PLANT BIOTECH APS (DK) 2005-05-24 US claimed
EP-1217884-A1 METHOD FOR MATURATION OF CONIFER SOMATIC EMBRYOS Woody Plant Biotech APS (DK) 2002-07-03 EP claimed
WO-2001020972-A1 METHOD FOR MATURATION OF CONIFER SOMATIC EMBRYOS WOODY PLANT BIOTECH APS (DK) 2001-03-29 WO claimed
US-10118916-B2 Modulators of cystic fibrosis transmembrane conductance regulator protein ABBVIE S.Á.R.L. (LU) 2018-11-06 US disclosed
WO-2017187321-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AbbVie S.à.r.l. (LU) 2017-11-02 WO disclosed
US-20170305891-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN ABBVIE S.Á.R.L. (LU) 2017-10-26 US disclosed
CN-101300005-B N-2 adamantyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors JANSSEN PHARMACEUTICA NV 2013-05-01 CN disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-8344181-B2 Obesity, type 2 diabetes, hyperlipidemia, hypertension, arteriosclerosis, coronary heart diseases JANSSEN PHARMACEUTICA N.V. (BE) 2013-01-01 US disclosed
EP-1575901-B1 SUBSTITUTED AMIDES MERCK SHARP & DOHME (US) 2012-10-10 EP disclosed
US-6897065-B1 Method for maturation of conifer somatic embryos WOODY PLANT BIOTECH APS (DK) 2005-05-24 US disclosed
EP-1496838-A2 SUBSTITUTED AMIDES Merck & Co., Inc. (US) 2005-01-19 EP disclosed
WO-2004058145-A2 SUBSTITUTED AMIDES MERCK & CO., INC. (US) 2004-07-15 WO disclosed
WO-2004048317-A1 SUBSTITUTED AMIDES ACTIVE AT THE CANNABINOID-1 RECEPTOR MERCK & CO., INC. (US) 2004-06-10 WO disclosed
US-20040058820-A1 Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis MERCK SHARP & DOHME LLC 2004-03-25 US disclosed
WO-2003077847-A2 SUBSTITUTED AMIDES MERCK & CO., INC. (US) 2003-09-25 WO disclosed
EP-1217884-A1 METHOD FOR MATURATION OF CONIFER SOMATIC EMBRYOS Woody Plant Biotech APS (DK) 2002-07-03 EP disclosed
WO-2001020972-A1 METHOD FOR MATURATION OF CONIFER SOMATIC EMBRYOS WOODY PLANT BIOTECH APS (DK) 2001-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305891-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN CFTR, CHRM2, CHRM1 PPARA 2278/4885CYP2C19 4157/4885MEN1 2068/4885
US-20040058820-A1 Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis CNR1, CNR2, MAG PPARA 780/4885CYP2C19 1058/4885MEN1 178/4885
US-10118916-B2 Modulators of cystic fibrosis transmembrane conductance regulator protein CFTR, CHRM2, CHRM1 PPARA 2278/4885CYP2C19 4157/4885MEN1 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.